Seminar Theatre 2

Wednesday 7th June

Thursday 8th June

speaker

11.00 - 11.30

Dr Naga Kandasamy

Stroke – New trends

The results of 5 randomised controlled trials in 2015 showed the efficacy of endovascular treatment over conventional stroke treatment (intravenous thrombolysis) in the management of stroke patients with large vessel occlusion. The current evidence base in the treatment of acute stroke is reviewed with a look into the challenges lying ahead in the implementation of the current evidence.

speaker

11.45 - 12.15

James S. Gyurke, Ph.D.

The importance of data based decision making in concussion management

This seminar will cover the critical elements of concussion identification and management for healthcare professionals. The focus will be on how reliable, valid and objective computerized assessment improves the decision-making process and the outcomes of the patient. Particular attention will be given to the key elements of a program including education, assessment and management and which stakeholders should be involved in each phase of the program. Examples of model programs from the US will be provided.

12.30 - 13.00

Jane Burridge

Intelligent Wearable Technology for Upper Limb Stroke Rehabilitation

Wearable technologies to support self-management can increase intensity of therapy. An example is M-MARK, a wearable system to support self-management of arm rehabilitation post-stroke, and provides therapists with detailed objective assessments of impairment such as range and smoothness of movement, muscle synergies and motor control. The neuroscience and motor learning principles that underpin the M-MARK concept, research process and key findings will be presented. M-MARK comprises a garment with embedded sensors measuring mechanical muscle activity (mechanomyography) and movement (Inertial Measurement Units). Data, recorded during everyday tasks, are transmitted via Bluetooth to a computer tablet and processed in real time. Novel algorithms provide meaningful metrics and visualisations for therapists and patients on amount and quality of movement. M-MARK has been designed, using a person-centred approach, by a multi-disciplinary team including engineers, therapists, patients and carers and two commercial partners. It has been tested for reliability and validity and will be CE marked and tested in a feasibility study.

speaker

13.15 - 13.45

Jennifer Legler, BS, CNIM

The Importance of Education and Training in Neurodiagnostics

The neurodiagnostic field is comprised of EEG, Evoked Potentials (EP), Nerve Conduction Studies (NCS),and Intraoperative Monitoring (IOM) and is rapidly evolving. IOM, for example, was first used in the 1970’s when severe spinal deformities could be treated with surgical advancements and instrumentation. At that time spinal cord evoked potentials were developed to reduce spinal cord injury. As the benefit of evoked potentials became apparent the field adapted to include Brainstem Evoked Potentials, Visual Evoked Potentials, and Direct Nerve Stimulation. However, the neurodiagnostics field grew, and is continuing to grow at such a rate that the opportunity and the availability for quality education did not keep up. But, technologists, surgeons, and companies are beginning to realize the need for quality education and training.

speaker

14.00 - 14.30

Dr Jeremy Isaacs

Diagnosis of young onset dementia

An increasing number of younger people are presenting in primary care and to memory and neurology clinics with concerns about their memory and other cognitive abilities. Only a small proportion have an underlying dementia; however, this is an important diagnosis with life changing consequences. Research suggests that people with young onset dementia experience significant delays in receiving a diagnosis. My talk will focus on the clinical assessment of younger people with cognitive symptoms, including features that help the clinician distinguish benign from pathological symptoms. I will discuss the major diagnoses in younger people in the cognitive clinic including neurodegenerative dementias such as Alzheimer’s disease and frontotemporal dementia and non-organic syndromes such as functional cognitive disorder.

speaker

14.45 - 15.15

Dr Hugo Spiers

Developing a mobile app help diagnose spatial navigation problems in early stage Alzheimer’s dementia

The seminar will introduce the audience to the app Sea Hero Quest, a mobile game that tests spatial navigation skills. From May 2016 – August 2016 more than 2.2 million people have played the game across the world. This provides an unprecedented baseline to compare patients with Alzheimer’s dementia against. We not only hope the test will be useful for diagnosis, but also beneficial for assessing decline or improvements in performance in potential drug trials.

speaker

15.30 - 16.00

Xavier Golay, Ph.D.

Image-based biomarkers of disease progression in dementia: current and future prospects

With the emergence of potential new disease-modifying molecules and other treatments for dementia comes the necessity to assess its efficacy in a time-efficient manner. Traditional approval for medicine have relied on the use of clinical endpoints, often based on lengthy interviews of patients and other neurological assessments. The typical noise associated with the use of these clinical scales makes it difficult to detect subtle benefits of potential new treatments over a short time, and as such there is a need for the development of other assessment strategies. Biomarkers report directly on one aspect of the disease, and image-based biomarkers have seen a rapid development over the last decade as an important tool to diagnose dementia and follow its progression. From the original biomarkers based on the quantitative assessment of grey matter depletion, either within the hippocampus or the whole brain, a whole new series of advanced imaging techniques have been developed, all providing complementary information on the state and advancement of the disease, from estimate of functional connectivity to baseline perfusion levels, and from structural integrity to amyloid and other protein aggregation. In this presentation, I will summarise some of the most important work done on image-based biomarkers recently, in particular through the ongoing large-scale initiatives such as the Alzheimer''s Disease Neuroimaging Initiative (ADNI).

speaker

16.15 - 16.45

Andrew Fahey

The Impact of IR35 on the NHS

This presentation includes a summary on the IR35 changes, details how Brookson Direct can assist with an effective IR35 reform implementation plan and explains how with our expert advice and training aids, Trusts can easily navigate the impending legislative changes.